AMPE vs. EVLO, GNCAQ, GNCA, ARDS, STAB, CMRA, EFTR, ONCSQ, PXMD, and ATNFW
Should you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), PaxMedica (PXMD), and 180 Life Sciences (ATNFW). These companies are all part of the "pharmaceutical products" industry.
Ampio Pharmaceuticals vs.
Evelo Biosciences (NASDAQ:EVLO) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Evelo Biosciences received 170 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 60.50% of users gave Evelo Biosciences an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.
Evelo Biosciences has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 3.9, suggesting that its stock price is 290% more volatile than the S&P 500.
0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Evelo Biosciences and Evelo Biosciences both had 1 articles in the media. Evelo Biosciences' average media sentiment score of 0.32 beat Ampio Pharmaceuticals' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.
Summary
Ampio Pharmaceuticals beats Evelo Biosciences on 4 of the 7 factors compared between the two stocks.
Get Ampio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ampio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:AMPE) was last updated on 5/22/2025 by MarketBeat.com Staff
